CLEARMIND MEDICINE INC.

Altre lingue Clearmind Medicine Inc.

Azioni

CMND

CA1850534027

Mercato chiuso - Nasdaq Altri mercati azionari 21:59:57 05/06/2024			Variaz. 5gg	Var. 1 gen.
1,07 ^USD	0,00%		-5,31%	-61,92%

10/05	Clearmind Medicine Inc. avanza il suo prodotto brevettato di bevanda alcolica sintetica a base di psichedelici	CI
07/05	Clearmind Medicine ottiene diritti esclusivi globali su composti psichedelici innovativi per il trattamento del PTSD	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	13/05
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	10/05
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	10/05
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	07/05
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	07/05
Clearmind Applies to Cease Being a Reporting Issuer in Canada	30/04
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders	17/04
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10/04
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10/04
Clearmind Medicine CEO Issues Letter to Shareholders	09/04
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression	27/03
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China	19/03
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration	19/03
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K	19/03
Clearmind Medicine Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	18/03
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals	08/03/22
Clearmind Medicine : Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board	14/10/21
Clearmind Medicine : to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20	01/10/21

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

-40% Proroga eccezionale: i nostri abbonamenti ti guidano verso i migliori investimenti di domani.

APPROFITTANE ORA